[논문]Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

Tepper, Stewart J.; Krege, John H.; Lombard, Louise; Asafu‐; Adjei, Josephine K.; Dowsett, Sherie A.; Raskin, Joel; Buchanan, Andrew S.; Friedman, Deborah I.

doi:10.1111/head.13544

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

Headache, v.59 no.7, 2019년, pp.1052 - 1062

Tepper, Stewart J. (Geisel School of Medicine at Dartmouth, Hanover, NH, USA) , Krege, John H. (Eli Lilly and Company, Indianapolis, IN, USA) , Lombard, Louise (Eli Lilly and Company, Indianapolis, IN, USA) , Asafu‐Adjei, Josephine K. (Eli Lilly and Company, Indianapolis, IN, USA) , Dowsett, Sherie A. (Eli Lilly and Company, Indianapolis, IN, USA) , Raskin, Joel (Eli Lilly and Company, Indianapolis, IN, USA) , Buchanan, Andrew S. (Eli Lilly and Company, Indianapolis, IN, USA) , Friedman, Deborah I. (University of Texas, Southwestern Medical Center, Dallas, TX, USA)

Abstract ▼ AI-Helper

Trial DesignSAMURAI and SPARTAN were double‐blind, placebo‐controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo within 4 hours of onset of a migraine attack. The aim of this analysis was to characterize dizziness reported with lasmiditan treatment.MethodsData from SAMURAI and SPARTAN were pooled for the current post hoc analyses. Onset time and duration of dizziness were analyzed using descriptive statistics. Subgroup analyses based on presence/absence of dizziness were performed for the endpoints of interference with daily activity, patient global impression of change (PGIC), pain at 2 hours, and most bothersome symptom (MBS) at 2 hours based on adverse events occurring within 2 hours of taking study drug.ResultsDizziness incidence was as follows: Placebo (N = 1262), 2.9% (0.1% severe); lasmiditan 50 mg (N = 654), 8.6% (0.3% severe); lasmiditan 100 mg (N = 1265), 14.9% (0.7% severe); and lasmiditan 200 mg (N = 1258), 16.8% (1.4% severe). Among participants who received lasmiditan as their first dose, risk factors for dizziness were higher lasmiditan dosage, being non‐Hispanic/Latino, mild or moderate severity of migraine attack, and lower body mass index. The median time to onset of dizziness was generally 30‐40 minutes, and the median duration was 1.5‐2 hours. The presence of dizziness did not appear to have a negative influence on lasmiditan's effect on daily activity, PGIC, freedom from pain, or MBS. Overall, 21 participants experienced vertigo: Lasmiditan 50 mg, n = 2 (0.3%); 100 mg, n = 11 (0.9%); 200 mg, n = 7 (0.6%); and placebo, n = 1 (<0.1%).ConclusionThe incidence of dizziness with lasmiditan increased with dose. Dizziness was generally mild or moderate in severity and of quick onset and short duration. The presence of dizziness did not influence drug efficacy.

주제어

참고문헌 (24)

Vila-Pueyo, Marta. Targeted 5-HT _1F Therapies for Migraine. Neurotherapeutics, vol.15, no.2, 291-303.

상세보기
Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain : a journal of neurology, vol.142, no.7, 1894-1904.

상세보기
Kuca, Bernice, Silberstein, Stephen D., Wietecha, Linda, Berg, Paul H., Dozier, Gregory, Lipton, Richard B.. Lasmiditan is an effective acute treatment for migraine : A phase 3 randomized study. Neurology, vol.91, no.24, e2222-e2232.

상세보기
Goldstein, DJ, Roon, KI, Offen, WW, Ramadan, NM, Phebus, LA, Johnson, KW, Schaus, JM, Ferrari, MD. Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. The Lancet, vol.358, no.9289, 1230-1234.

상세보기
Gallagher, R. Michael, Kunkel, Robert. Migraine Medication Attributes Important for Patient Compliance: Concerns About Side Effects May Delay Treatment. Headache, vol.43, no.1, 36-43.

상세보기
Dodick, DW, Martin, V. Triptans and CNS Side-Effects : pharmacokinetic and metabolic mechanisms. Cephalalgia : an international journal of headache, vol.24, no.6, 417-424.

상세보기
Stewart, W.F., Lipton, R.B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J.N., Sawyer, J.. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology, vol.53, no.5, 988-988.

상세보기
Stewart, WF, Lipton, RB, Kolodner, K, Liberman, J, Sawyer, J. Reliability of the Migraine Disability Assessment Score in A Population-Based Sample of Headache Sufferers. Cephalalgia : an international journal of headache, vol.19, no.2, 107-114.

상세보기
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., Stewart, W. F.. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, vol.68, no.5, 343-349.

상세보기
Cady, Roger K., Martin, Vincent T., Géraud, Gilles, Rodgers, Anthony, Zhang, Ying, Ho, Andrew P., Hustad, Carolyn M., Ho, Tony W., Connor, Kathryn M., Ramsey, Karen E.. Rizatriptan 10-mg ODT for Early Treatment of Migraine and Impact of Migraine Education on Treatment Response. Headache, vol.49, no.5, 687-696.

상세보기
Dodick, David, Brandes, Jan, Elkind, Arthur, Mathew, Ninan, Rodichok, Lawrence. Speed of Onset, Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine : A Randomised, Double-Blind, Placebo-Controlled Study. Cns drugs, vol.19, no.2, 125-136.

상세보기
Cady, Roger K, McAllister, Peter J, Spierings, Egilius LH, Messina, John, Carothers, Jennifer, Djupesland, Per G, Mahmoud, Ramy A. A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study). Headache, vol.55, no.1, 88-100.

상세보기
Ho, T.W., Ferrari, M.D., Dodick, D.W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., Koppen, H., Winner, P.K.. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. The Lancet, vol.372, no.9656, 2115-2123.

상세보기
MedGenMed Landy S 53 9 2007 Two double‐blind, multicenter, randomized, placebo‐controlled, single‐dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: Function, productivity, and satisfaction outcomes
ECDEU Assessment Manual for Psychopharmacology‐Revised Guy W 218 1976
10.1017/CBO9780511802843
Efron, Bradley. Better Bootstrap Confidence Intervals. Journal of the American Statistical Association, vol.82, no.397, 171-185.

상세보기
Cephalalgia Pilgrim A 24 29 2009 Col‐144, an orally bioavailable selective 5‐HT1F receptor agonist for acute migraine therapy: Po34
Imitrex.GlaxoSmithKline;2017. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020132s029lbl.pdf. Accessed February 8 2019.
Maxalt.MSD Ltd;2011. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020864s011s016s017s018s019 020865s012s016s018s020s021lbl.pdf. Accessed February 8 2019.
Amerge.GlaxoSmithKline;2016. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020763s011lbl.pdf. Accessed February 8 2019.
Relpax.Pfizer;2013. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021016s021s023s024s027lbl.pdf. Accessed February 8 2019.
Zomig.AstraZeneca;2018. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023 021231s014 021450s010lbl.pdf. Accessed February 8 2019.
An Open‐label Long‐term Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR). ClinicalTrials.gov Registration Number NCT02565186.ClinicalTrials.gov;2015.

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

Abstract ▼ AI-Helper

주제어

참고문헌 (24)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트